Advertisement
Document › Details
Sartorius AG. (8/8/22). "Press Release: Sartorius to Acquire Albumedix, Strengthening Its Portfolio of Innovative Advanced Therapy Solutions". Göttingen.
> UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company
> Recombinant human albumin is a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines
> Sartorius will acquire all outstanding shares of Albumedix Ltd. for approximately £415 million
The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.
“Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones,” said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.
“We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We remain focused on our promise of empowering excellence in the life science industry,” said Jonas S. Møller, CEO of Albumedix.
Albumedix will be part of the Bioprocess Solutions Division, and the existing 72,000-square-foot site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials.
Milbank LLP provided legal counsel to Sartorius in this transaction. William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal counsel.
This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Contact Media Relations
Philipp Grontzki
Head of External Communications
+49 (0)551.308.5581
philipp.grontzki@sartorius.com
Contact Investor Relations
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Record changed: 2023-06-05 |
Advertisement
More documents for Sartorius (Group)
- [1] va-Q-tec AG. (4/26/23). "Press Release: Sartorius and va-Q-tec Announce a Long-term Partnership for the Joint Development of Innovative Transport Systems for the Biopharmaceutical Industry". Würzburg & Göttingen....
- [2] Sartorius AG. (12/8/22). "Press Release: Sartorius Agrees with Bico on Strategic Cooperation as well as a 10 Percent Capital Investment". Göttingen....
- [3] Sartorius AG. (11/11/22). "Press Release: Sartorius Successfully Places Schuldschein Loans with a Volume of 650 Million Euros". Göttingen....
- [4] Sartorius AG. (9/30/22). "Press Release: Sartorius Completes Acquisition of Albumedix". Göttingen....
- [5] Albumedix Ltd.. (6/1/20). "Press Release: Albumedix Announces Appointment of Gregor Kawaletz as Chief Commercial Officer"....
- [6] Albumedix Ltd.. (5/26/20). "Press Release: Albumedix Announces Jonas Skjødt Møller as New Chief Executive Officer"....
- [7] Genedata AG. (5/2/19). "Press Release: Out-of-the-Box Integration of Genedata Bioprocess with MODDE Streamlines Bioprocess Development DOE". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top